{"id":"antitumor-b","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL1160385","moleculeType":"Small molecule","molecularWeight":"182.27"},"_dailymed":{"setId":"19132c86-6b65-7c1b-e063-6294a90a0280","title":"SALANA 153 (BLOOD CIRCULATION, CYTOTHESIS, THROMBOLYSIS, IMMUNITY BOOST, AN ANTITUMOR, ANTIINFLAMMATORY, REGULATORY ACTION, INHIBITORY ACTION, EXOCYTOSIS) (NORUGUNG DEW MUSHROOM) LIQUID [BIOHERB CO., LTD.]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Antitumor B targets and binds to specific molecular pathways involved in cancer cell growth and survival, ultimately leading to the death of cancer cells. This mechanism of action is specific to rapidly dividing cells, making it effective against various types of cancer.","oneSentence":"Antitumor B works by inhibiting cell proliferation and inducing apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:53:25.122Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT05768932","phase":"PHASE1","title":"BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"SillaJen, Inc.","startDate":"2022-12-14","conditions":"Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer","enrollment":260},{"nctId":"NCT06630806","phase":"PHASE1","title":"A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-10-30","conditions":"Plasma Cell Myeloma Refractory","enrollment":87},{"nctId":"NCT06166836","phase":"PHASE1, PHASE2","title":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2022-10-12","conditions":"Solid Tumor","enrollment":140},{"nctId":"NCT04278989","phase":"EARLY_PHASE1","title":"Inhibition of Oral Tumorigenesis by Antitumor B","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2022-04-22","conditions":"Squamous Cell Cancer of the Oral Cavity","enrollment":30},{"nctId":"NCT06482905","phase":"PHASE1","title":"Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.","status":"RECRUITING","sponsor":"Tcelltech Inc.","startDate":"2024-09-04","conditions":"High-grade Glioma, WHO Grade Ⅳ Glioma","enrollment":52},{"nctId":"NCT07229638","phase":"PHASE1, PHASE2","title":"A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-02-27","conditions":"Solid Tumor","enrollment":70},{"nctId":"NCT05948865","phase":"PHASE1","title":"A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Conjupro Biotherapeutics, Inc.","startDate":"2023-06-06","conditions":"Cancer, Cancer, Lung","enrollment":132},{"nctId":"NCT05661955","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-01-09","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma","enrollment":113},{"nctId":"NCT06898450","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Nimbus Wadjet, Inc.","startDate":"2025-03-31","conditions":"Advanced Solid Tumors Cancer, MSI-H Cancer","enrollment":134},{"nctId":"NCT06589596","phase":"PHASE1","title":"An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-10-11","conditions":"Advanced Solid Tumor","enrollment":244},{"nctId":"NCT06596473","phase":"PHASE1","title":"A Study of BG-C477 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-10-03","conditions":"Advanced Solid Tumors","enrollment":310},{"nctId":"NCT06052306","phase":"PHASE1","title":"A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2023-09-20","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":232},{"nctId":"NCT07226349","phase":"PHASE1","title":"A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-12-11","conditions":"Advanced Solid Tumor","enrollment":105},{"nctId":"NCT06585488","phase":"PHASE1","title":"A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification","status":"RECRUITING","sponsor":"BeiGene","startDate":"2024-11-26","conditions":"Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer","enrollment":514},{"nctId":"NCT06487858","phase":"PHASE1","title":"A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-07-16","conditions":"Solid Tumor","enrollment":75},{"nctId":"NCT06427941","phase":"PHASE1","title":"A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-07-23","conditions":"Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer","enrollment":140},{"nctId":"NCT04077463","phase":"PHASE1","title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":701},{"nctId":"NCT06540066","phase":"PHASE1","title":"A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"BeiGene","startDate":"2024-09-11","conditions":"Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer","enrollment":35},{"nctId":"NCT05935098","phase":"PHASE1","title":"BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors","status":"TERMINATED","sponsor":"BeiGene","startDate":"2023-08-21","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor","enrollment":99},{"nctId":"NCT05557045","phase":"PHASE1","title":"A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815","status":"RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2022-10-10","conditions":"Advanced Cancer, Metastatic Cancer, Solid Tumor","enrollment":332},{"nctId":"NCT06598800","phase":"PHASE1","title":"Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeiGene","startDate":"2024-10-18","conditions":"Advanced Solid Tumor","enrollment":87},{"nctId":"NCT07460362","phase":"PHASE2","title":"Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-08-11","conditions":"MCL, Relapsed or Refractory Mantle Cell Lymphoma (MCL)","enrollment":43},{"nctId":"NCT05573555","phase":"PHASE1, PHASE2","title":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-03-01","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT06656390","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Allink Biotherapeutics Co., Ltd.","startDate":"2024-10-24","conditions":"Advanced Cancer, Advanced Solid Tumors","enrollment":202},{"nctId":"NCT07455188","phase":"","title":"A Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-03-01","conditions":"Breast Cancer","enrollment":600},{"nctId":"NCT03203525","phase":"PHASE1","title":"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-06-23","conditions":"Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver, Metastatic Malignant Neoplasm in the Liver","enrollment":38},{"nctId":"NCT07181681","phase":"PHASE1","title":"A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-11-10","conditions":"Solid Tumors, Advanced Solid Tumor","enrollment":63},{"nctId":"NCT06422520","phase":"PHASE1","title":"A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2024-07-08","conditions":"Advanced Solid Tumor","enrollment":120},{"nctId":"NCT04379596","phase":"PHASE2","title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2020-06-03","conditions":"Gastric Cancer","enrollment":450},{"nctId":"NCT07193511","phase":"PHASE1, PHASE2","title":"BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)","status":"RECRUITING","sponsor":"Avenzo Therapeutics, Inc.","startDate":"2025-10-02","conditions":"Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors","enrollment":355},{"nctId":"NCT06625593","phase":"PHASE1","title":"A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-12-09","conditions":"Advanced Solid Tumor","enrollment":168},{"nctId":"NCT05381909","phase":"PHASE1","title":"A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors","status":"TERMINATED","sponsor":"BeiGene","startDate":"2022-07-06","conditions":"Solid Tumor, Adult","enrollment":157},{"nctId":"NCT07038343","phase":"PHASE1, PHASE2","title":"AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)","status":"RECRUITING","sponsor":"Avenzo Therapeutics, Inc.","startDate":"2025-06-04","conditions":"Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors","enrollment":430},{"nctId":"NCT04649385","phase":"PHASE1","title":"BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2021-03-04","conditions":"Advanced Solid Tumor","enrollment":157},{"nctId":"NCT07421700","phase":"PHASE1, PHASE2","title":"A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-02-27","conditions":"Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma","enrollment":132},{"nctId":"NCT04666740","phase":"PHASE2","title":"A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-12-18","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, Homologous Recombination Deficiency (HRD)","enrollment":63},{"nctId":"NCT07414836","phase":"PHASE1","title":"A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"BeOne Medicines","startDate":"2026-04-30","conditions":"Advanced Solid Tumor","enrollment":84},{"nctId":"NCT05579132","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)","status":"RECRUITING","sponsor":"MSD R&D (China) Co., Ltd.","startDate":"2022-11-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":203},{"nctId":"NCT06217822","phase":"PHASE1","title":"First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-03-07","conditions":"Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression","enrollment":198},{"nctId":"NCT07381764","phase":"PHASE2","title":"ROMANCE: \"Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer\"","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico Italia Meridionale","startDate":"2026-03-30","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":150},{"nctId":"NCT02143466","phase":"PHASE1","title":"AZD9291 in Combination With Ascending Doses of Novel Therapeutics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-08-05","conditions":"Advanced Non Small Cell Lung Cancer","enrollment":344},{"nctId":"NCT06634199","phase":"","title":"Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients","status":"RECRUITING","sponsor":"Fundación GECP","startDate":"2024-10-03","conditions":"Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation","enrollment":50},{"nctId":"NCT05327530","phase":"PHASE2","title":"A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)","status":"ACTIVE_NOT_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-08-17","conditions":"Locally Advanced or Metastatic Urothelial Carcinoma","enrollment":256},{"nctId":"NCT04733027","phase":"EARLY_PHASE1","title":"First-in-human Phase I to Evaluate PEP-010 as Single Agent and in Combination With Paclitaxel or With Gemcitabine (CleverPeptide)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Curie","startDate":"2021-05-18","conditions":"Metastatic Solid Tumor Cancer","enrollment":57},{"nctId":"NCT07355361","phase":"PHASE2","title":"Huaier Granule and Proteinuria","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-15","conditions":"Proteinuria, Breast Cancer Patients","enrollment":120},{"nctId":"NCT05002270","phase":"PHASE1, PHASE2","title":"JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation","status":"COMPLETED","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","startDate":"2021-09-03","conditions":"Advanced Solid Tumor, NSCLC, CRC","enrollment":29},{"nctId":"NCT02337829","phase":"PHASE2","title":"Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2015-01-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":48},{"nctId":"NCT03905148","phase":"PHASE1","title":"Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-05-01","conditions":"Solid Tumor, Adult","enrollment":91},{"nctId":"NCT05174585","phase":"PHASE1, PHASE2","title":"JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","startDate":"2022-08-18","conditions":"Solid Tumor","enrollment":21},{"nctId":"NCT07298772","phase":"PHASE1, PHASE2","title":"A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-12","conditions":"Advanced Solid Tumor","enrollment":198},{"nctId":"NCT06512051","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-07-30","conditions":"Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":248},{"nctId":"NCT04883957","phase":"PHASE1","title":"Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2021-07-05","conditions":"Mature B-cell Malignancies","enrollment":64},{"nctId":"NCT06387121","phase":"PHASE2","title":"Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-02","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":53},{"nctId":"NCT07280793","phase":"EARLY_PHASE1","title":"CAR-T Cell Efficacy With Molecular Imaging in Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Xuzhou Medical University","startDate":"2025-12-17","conditions":"Non-invasive CAR-T Cell Monitoring, BCMA-targeted PET Imaging, CAR-T Cell Biodistribution and Persistence","enrollment":10},{"nctId":"NCT06609005","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Shenzhen Ionova Life Sciences Co., Ltd.","startDate":"2025-01-23","conditions":"Advanced Metastatic Castration Resistant Prostate Cancer","enrollment":84},{"nctId":"NCT07232849","phase":"PHASE2","title":"A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12-04","conditions":"Lung Cancer","enrollment":100},{"nctId":"NCT04381650","phase":"PHASE1, PHASE2","title":"A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-08-17","conditions":"Advanced or Metastatic Solid Tumors","enrollment":161},{"nctId":"NCT03307785","phase":"PHASE1","title":"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-10-12","conditions":"Neoplasms, Metastatic Cancer, Advanced Cancer","enrollment":60},{"nctId":"NCT07245251","phase":"NA","title":"To Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of STR-P004","status":"NOT_YET_RECRUITING","sponsor":"Starna Therapeutics","startDate":"2025-12-03","conditions":"Acute Lymphobkastic Leukemia","enrollment":11},{"nctId":"NCT04215978","phase":"PHASE1","title":"Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2020-01-30","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":204},{"nctId":"NCT03744468","phase":"PHASE1, PHASE2","title":"Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-11-13","conditions":"Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2","enrollment":114},{"nctId":"NCT04993690","phase":"PHASE1","title":"A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma","status":"RECRUITING","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","startDate":"2021-07-06","conditions":"B-cell Lymphoma","enrollment":200},{"nctId":"NCT06285097","phase":"PHASE1","title":"A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2024-02-08","conditions":"Neoplasms, Non-small-cell Lung Cancer, Melanoma","enrollment":9},{"nctId":"NCT05904496","phase":"PHASE1","title":"A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"BeiGene","startDate":"2023-07-19","conditions":"Advanced Solid Tumors","enrollment":44},{"nctId":"NCT05267054","phase":"PHASE1, PHASE2","title":"Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab","status":"COMPLETED","sponsor":"BeiGene","startDate":"2022-04-25","conditions":"Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma","enrollment":53},{"nctId":"NCT05822843","phase":"PHASE1","title":"A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies","status":"COMPLETED","sponsor":"Shanghai Escugen Biotechnology Co., Ltd","startDate":"2023-08-02","conditions":"B-cell Lymphoid Malignancies","enrollment":13},{"nctId":"NCT05263739","phase":"PHASE1","title":"A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies","status":"WITHDRAWN","sponsor":"Shanghai Escugen Biotechnology Co., Ltd","startDate":"2025-12","conditions":"B-cell Lymphoid Malignancies","enrollment":""},{"nctId":"NCT07102901","phase":"PHASE2","title":"Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-09-05","conditions":"Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":351},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT06840886","phase":"PHASE1","title":"A Study of PHST001 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Pheast Therapeutics","startDate":"2025-03-31","conditions":"Advanced Solid Tumors","enrollment":155},{"nctId":"NCT07124936","phase":"PHASE1, PHASE2","title":"A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-07-30","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":97},{"nctId":"NCT05660473","phase":"PHASE2","title":"Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-08-01","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":100},{"nctId":"NCT04522323","phase":"PHASE1","title":"A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2020-08-05","conditions":"Advanced Renal Cell Carcinoma","enrollment":67},{"nctId":"NCT05329103","phase":"PHASE1","title":"A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Peel Therapeutics Inc","startDate":"2022-07-11","conditions":"Advanced Solid Tumor","enrollment":65},{"nctId":"NCT04332744","phase":"PHASE2","title":"Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-09-02","conditions":"Metastatic Prostate Cancer","enrollment":54},{"nctId":"NCT05067972","phase":"PHASE1","title":"A Study of PF-07260437 in Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2021-10-07","conditions":"Ovarian Neoplasms, Endometrial Neoplasms, Breast Neoplasms","enrollment":30},{"nctId":"NCT05494762","phase":"PHASE1","title":"Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"BeiGene","startDate":"2022-08-25","conditions":"Solid Tumor","enrollment":55},{"nctId":"NCT06944444","phase":"PHASE1","title":"A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors","status":"RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2025-04-27","conditions":"Malignant Tumors","enrollment":154},{"nctId":"NCT04256707","phase":"PHASE1, PHASE2","title":"Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-01-14","conditions":"Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors","enrollment":126},{"nctId":"NCT05452408","phase":"PHASE1","title":"Antitumor-B KAC PK Study","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2026-12","conditions":"Squamous Cell Carcinoma of the Oral Cavity","enrollment":""},{"nctId":"NCT06707610","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Allink Biotherapeutics Co., Ltd.","startDate":"2025-02-10","conditions":"Advanced Cancer, Advanced Solid Tumor","enrollment":234},{"nctId":"NCT04805307","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901","status":"COMPLETED","sponsor":"Keymed Biosciences Co.Ltd","startDate":"2020-12-24","conditions":"Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma), Pancreatic Cancer","enrollment":176},{"nctId":"NCT06792435","phase":"PHASE1, PHASE2","title":"XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.","status":"RECRUITING","sponsor":"Evopoint Biosciences Inc.","startDate":"2023-07-27","conditions":"Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer","enrollment":240},{"nctId":"NCT02743546","phase":"PHASE1","title":"Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2016-07-20","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular","enrollment":""},{"nctId":"NCT04887259","phase":"PHASE1","title":"Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML","status":"TERMINATED","sponsor":"Lava Therapeutics","startDate":"2021-07-12","conditions":"Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia","enrollment":16},{"nctId":"NCT03459729","phase":"EARLY_PHASE1","title":"Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2021-08-24","conditions":"Squamous Cell Carcinoma of the Oral Cavity","enrollment":6},{"nctId":"NCT06772454","phase":"","title":"To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand 1 (PD-L1) Inhibitor Plus Platinum-based Chemotherapy in Patients With Advanced Lung Squamous Cell Carcinoma Complicated With Chronic Obstructive Pulmonary Disease (COPD)","status":"RECRUITING","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2023-01-01","conditions":"Lung Cancer Squamous Cell, COPD","enrollment":60},{"nctId":"NCT06474468","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-06-20","conditions":"Advanced or Metastatic Esophageal Cancer","enrollment":148},{"nctId":"NCT05145569","phase":"PHASE2","title":"Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer","status":"WITHDRAWN","sponsor":"Haider Mahdi","startDate":"2024-05-10","conditions":"Ovarian Cancer","enrollment":""},{"nctId":"NCT06417554","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-05-13","conditions":"Advanced Solid Tumors","enrollment":80},{"nctId":"NCT02610361","phase":"PHASE1","title":"Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2013-11-20","conditions":"Solid Tumors","enrollment":131},{"nctId":"NCT06034275","phase":"PHASE1","title":"Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies","status":"RECRUITING","sponsor":"Vincerx Pharma, Inc.","startDate":"2023-09-13","conditions":"Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome","enrollment":36},{"nctId":"NCT05650242","phase":"PHASE1","title":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shandong Boan Biotechnology Co., Ltd","startDate":"2023-01-31","conditions":"Solid Tumors","enrollment":177},{"nctId":"NCT06652529","phase":"PHASE1","title":"Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Aromics Therapeutics","startDate":"2025-01","conditions":"Solid Tumors (Phase 1), Mesothelioma, Colorectal Carcinoma","enrollment":35},{"nctId":"NCT06662669","phase":"PHASE1, PHASE2","title":"YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","startDate":"2024-11-30","conditions":"Metastatic Pancreatic Cancer","enrollment":120},{"nctId":"NCT02569476","phase":"PHASE1","title":"BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies","status":"COMPLETED","sponsor":"BeiGene","startDate":"2016-01-13","conditions":"B-cell Lymphoid Malignancies","enrollment":119},{"nctId":"NCT03432598","phase":"PHASE2","title":"Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2017-08-24","conditions":"Locally Advanced Lung Cancer; Metastatic Lung Cancer","enrollment":54},{"nctId":"NCT03530683","phase":"PHASE1","title":"A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-05-14","conditions":"Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia","enrollment":189},{"nctId":"NCT04931823","phase":"PHASE1","title":"Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Conjupro Biotherapeutics, Inc.","startDate":"2021-03-24","conditions":"Solid Tumor","enrollment":126},{"nctId":"NCT04349969","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104","status":"COMPLETED","sponsor":"Akesobio Australia Pty Ltd","startDate":"2020-04-23","conditions":"Neoplasms Malignant","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zeng Sheng Ping","ATB","ACAPHA"],"phase":"marketed","status":"active","brandName":"Antitumor B","genericName":"Antitumor B","companyName":"Medical College of Wisconsin","companyId":"medical-college-of-wisconsin","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antitumor B works by inhibiting cell proliferation and inducing apoptosis in cancer cells. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}